CD4 and hepatocellular carcinoma: These findings are consistent with earlier reports, in patients with hepatocellular carcinomas (HCCs), where it has also been demonstrated that sub-pharmacologic doses of sorafenib have unique effects on various subsets of T cells, preferentially increasing Teff (CD4+CD25-) activation and suppressing Treg (CD4+CD25+) activity (39–41, 48).